newsfilter
← Latest News
GlobeNewswire·

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 ("‘2510") anticipated before the end of 2025 Updated ‘2510 monotherapy data in squamous-NSCLC to be presented at IASLC's 2025